Stroke · 2004 · 48 citations · 16 references
MedicineCardiologyNeurologyCardiovascular PharmacotherapyClinical PharmacologyPharmacovigilanceAntithrombotic TherapyCerebrovascular DiseasePatent Foramen OvaleStrokeThrombosisValvular Heart DiseaseAcute Adverse EventsAcute Ischemic Stroke TreatmentCryptogenic Stroke PreventionPatent Foramen Ovale PrevalencePost-stroke Antithrombotic TherapyRecurrent Stroke Prevention
BACKGROUND: Valvular strands are associated with ischemic stroke. The recurrent rate of adverse events in stroke patients with valvular strands has not been defined and, importantly, there are no randomized studies to evaluate efficacy of antithrombotic therapies in these patients. METHODS: Patent Foramen Ovale in Cryptogenic Stroke Study (PICSS) enrolled 630 stroke patients, of whom 312 (49.5%) were randomized to warfarin and 318 (50.5%) were randomized to aspirin; 265 patients experienced cryptogenic stroke and 365 experienced stroke with known subtypes. Endpoints were recurrent ischemic stroke or death from any cause. All transesophageal echocardiography studies were blindly, centrally analyzed and all endpoints were blindly adjudicated. RESULTS: Overall, of 619 studies analyzed, valvular strands were present in 39.4% of the patients (244/619), 5.8% (36/619) on the aortic valve and 27.8% (172/619) on the mitral valve, and 5.8% (36/619) on both valves. In an intention-to-treat analysis, there was no significant difference in the time to primary endpoints between patients with and without strands in the overall population (P=0.82; hazard ratio: 1.05; 95% CI: 0.70 to 1.57; 2-year event rates: 16.4% versus 15.5%). Among the patients with strands, there was no significant difference in the time to primary endpoints between those treated with warfarin or aspirin (P=0.21; hazard ratio: 0.67; 95% CI: 0.36 to 1.26; 2-year event rates: 13.5% versus 19.6%). CONCLUSIONS: While on medical therapy, valvular strands do not significantly increase recurrent adverse event rates in patients with ischemic stroke. Furthermore, the study does not provide evidence to support an advantage of warfarin or aspirin for this purpose.
16
Harold P. Adams, Birgitte H. Bendixen, L. Jaap Kappelle et al. · Stroke · 1993 · 12.3K citations · Full text
Effect of Medical Treatment in Stroke Patients With Patent Foramen Ovale
Shunichi Homma, Ralph L. Sacco, Marco R. Di Tullio et al. · Circulation · 2002 · 950 citations · Full text
Medicine, Neurology, Pharmacotherapy +15
Enhanced detection of intracardiac sources of cerebral emboli by transesophageal echocardiography.
R J Lee, Thomas C. Bartzokis, Thomas Yeoh et al. · Stroke · 1991 · 241 citations · Full text
Medicine, Cardiology, Radiology +17
Glasgow Outcome Scale: An inter-rater reliability study
Shirley Anderson, Alma M. Housley, Patricia A. Jones et al. · Brain Injury · 1993 · 120 citations